$5.410
+79.647 (+1472.22%)收盤時
NUWE 資訊
NUWE 事件
Nuwellis Inc Trading Halted, News Pending
Nuwellis Inc trading halted, news pending
Nuwellis Sells 31 Aquadex Systems in 2026
Nuwellis announced continued commercial momentum for its Aquadex SmartFlow system, with 31 consoles sold year-to-date in 2026. The company's year-to-date console performance already exceeds full-year console sales in seven of the past 10 years and puts Nuwellis on pace for one of its top three years for console sales. The expanding installed base comes alongside broader commercial momentum, including 26% year-over-year U.S. revenue growth during the first half of 2026.
Nuwellis and Atrility Medical Enter Co-Promotion Agreement
Nuwellis and Atrility Medical announced that they have entered into a co-promotion and distribution agreement for Atrility's AtriAmp device. Under the agreement, the companies will begin an initial six-month co-promotion program covering three Nuwellis sales territories across approximately nine Western and five Southeastern states. Atrility will continue to serve its existing customers in the covered territories, while Nuwellis will support those accounts and pursue new customer relationships through its established commercial presence in pediatric and adult critical care. Nuwellis will receive commissions on sales to existing and new customers within the covered territories. Upon successful completion of the pilot, Nuwellis is expected to transition to Atrility's exclusive U.S. distributor for much of the country.
Nuwellis Enters Agreement to Sell 1,310,890 Shares at $2.59
Nuwellis announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,310,890 shares of the Company's common stock at a price of $2.59 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Nuwellis also received approximately $3.1 Million in gross proceeds from the exercise of previously issued warrants which were issued in connection with the Company's June 2026 public offering. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offerings.
Nuwellis Secures Patent for Dual Lumen Catheter
Nuwellis announced that the U.S. Patent and Trademark Office , or USPTO, has issued U.S. Patent No. 12,678,592, covering the company's Dual Lumen Catheter, a peripheral dual-lumen catheter designed for use with extracorporeal therapies, including ultrafiltration, dialysis, and continuous renal replacement therapy modalities. The patent was issued on July 14.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。